Child Health Research Center
儿童健康研究中心
基本信息
- 批准号:10300437
- 负责人:
- 金额:$ 42.52万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-03-01 至 2022-11-30
- 项目状态:已结题
- 来源:
- 关键词:2 year oldAreaBasic ScienceBenchmarkingBioinformaticsBiologyCellular biologyChild HealthChild SupportChildhoodCore FacilityCryoelectron MicroscopyDNA sequencingDevelopmentDevelopmental BiologyDisciplineDiseaseDoctor of MedicineDoctor of PhilosophyFacultyFeedbackFosteringFundingGenerationsGeneticGenomicsGoalsHumanImageImmunologyInvestigationKnowledgeLaboratoriesLeadershipMedical centerMentorsPathway interactionsPhysiciansPlayResearchResearch PersonnelRoleSECTM1 geneScientistSystems BiologyTrainingUnderrepresented MinorityUniversitiesWashingtonWomananimal model developmentbasebiomedical resourcecareer developmentdevelopmental diseaseexomeexperiencegenome editingimprovedlive cell imagingmedical schoolsnext generationpediatric departmentprogramsresponsible research conductrole modelstatisticswhole genome
项目摘要
Project Summary Abstract
This renewal application (RFA-HD-18-011) is for support of the Child Health Research Center
(CHRC) at Washington University School of Medicine. Pediatric physician-scientists play a crucial
role in advancing knowledge that improves child health. To meet the ongoing national need to
replenish the pediatric physician-scientist pipeline at the junior faculty level, our program supports a
mentored career development pathway for 3 Scholars per year for 2-3 years by leveraging a wealth of
biomedical resources within the Washington University School of Medicine and the Medical Center
campus. As we have done for the past 22 years, the long-term objective of our Center is to develop
Scholars that focus their research efforts on Pediatric disease-oriented biology by applying recent
advances in the basic sciences, such as developmental biology, cell biology, immunology,
genetics/genomics, and systems biology. The specific aims of this proposal include: 1) protected
mentored research experiences with well-established investigators encompassing a wide range of
disciplines within the Washington University School of Medicine and the Department of Pediatrics, 2)
obligatory educational programs in laboratory management, scientific rigor, statistics, grantsmanship
and responsible conduct of research, 3) individualized specific coursework based on the Scholars’
areas of investigation (e.g., bioinformatics, live-cell imaging), 4) continuous feedback to the Scholars,
mentors and CHRC leadership, and 5) foster the development of Scholars who are women and
underrepresented minorities. The program, now twenty-two years old, has a stellar track record by
exceeding national benchmarks (”K12 to K08/23” conversion rate of 63% and an outstanding “K to R
conversion” rate of 59%; national average <40%, respectively), and will ultimately close the
knowledge gap between basic scientists and pediatric clinicians. Gary A. Silverman, M.D., Ph.D. will
serve as Program Director, and David Hunstad, M.D. will serve as Training Director. The CHRC and
its Scholars will continue to utilize our institutionally-funded state-of-art core facilities that provide, for
example, whole genome/exome DNA sequencing, bioinformatics, cryo-EM imaging, genome editing
and model animal development, to facilitate the study of Pediatric disease states. The long-term goals
of the CHRC are being realized as its Scholars contribute to our understanding of human
developmental diseases for decades to come, while evolving into the next generation of scientific
leaders, role models and mentors for subsequent generations of Pediatric Scholars.
项目摘要摘要
此更新应用程序(RFA-HD-18-011)是为了支持儿童健康研究中心
(CHRC)华盛顿大学医学院。小儿身体科学家发挥着重要的作用
在提高改善儿童健康的知识方面的角色。满足持续不断的国家需求
在初级教师级别补充小儿身体科学家管道,我们的计划支持
通过利用丰富的财富,每年3年的职业发展途径为2 - 3年
华盛顿大学医学院和医学中心的生物医学资源
校园。正如我们在过去22年中所做的那样,我们中心的长期目标是发展
通过应用最近
基础科学的进步,例如发育生物学,细胞生物学,免疫学,
遗传学/基因组学和系统生物学。该提案的具体目的包括:1)受保护
与成熟的研究人员一起进行的研究经验,包括广泛的
华盛顿大学医学院和儿科系的学科,2)
实验室管理,科学严谨,统计,授予技巧的强制性教育计划
和负责任的研究,3)基于学者的个性化特定课程
投资领域(例如,生物信息学,现场电池成像),4)对学者的持续反馈,
导师和CHRC领导,以及5)促进妇女学者的发展以及
代表性不足的少数民族。该节目现已二十二年,拥有出色的往绩记录
超过国家基准(“ K12至K08/23”的转换率为63%,而“ K到R)
转换率”为59%;全国平均水平<40%),最终将关闭
基本科学家与儿科临床医生之间的知识差距。 Gary A. Silverman,医学博士,博士将要
担任计划总监,医学博士David Hunstad将担任培训主任。 CHRC和
它的学者将继续利用我们提供的机构资助的最新核心设施,这些设施为
例如,整个基因组/外显子组DNA测序,生物信息学,冷冻EM成像,基因组编辑
并建模动物发展,以促进小儿疾病状态的研究。长期目标
由于学者有助于我们对人类的理解,因此正在实现CHR。
发育疾病几十年来,同时发展成为下一代的科学疾病
后来的儿科学者的领导者,榜样和导师。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GARY ARTHUR SILVERMAN其他文献
GARY ARTHUR SILVERMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GARY ARTHUR SILVERMAN', 18)}}的其他基金
Drug Therapies Identified through Modeling AT Deficiency in C Elegans
通过线虫 AT 缺陷建模确定药物治疗
- 批准号:
10197890 - 财政年份:2012
- 资助金额:
$ 42.52万 - 项目类别:
Drug Therapies Identified through Modeling AT Deficiency in C Elegans
通过线虫 AT 缺陷建模确定药物治疗
- 批准号:
10441252 - 财政年份:2012
- 资助金额:
$ 42.52万 - 项目类别:
Drug Therapies Identified through Modeling AT Deficiency in C Elegans
通过线虫 AT 缺陷建模确定药物治疗
- 批准号:
10630352 - 财政年份:2012
- 资助金额:
$ 42.52万 - 项目类别:
High Throughput Genetic and Drug Screens for Alph-1-Antitrypsin Deficiency
针对 Alph-1-抗胰蛋白酶缺乏症的高通量遗传和药物筛选
- 批准号:
8013391 - 财政年份:2010
- 资助金额:
$ 42.52万 - 项目类别:
Intracellular Serpin Regulation of Intestinal Cell Necrosis
细胞内丝氨酸蛋白酶抑制剂对肠细胞坏死的调节
- 批准号:
8321042 - 财政年份:2009
- 资助金额:
$ 42.52万 - 项目类别:
High Throughput Genetic and Drug Screens for Alph-1-Antitrypsin Deficiency
针对 Alph-1-抗胰蛋白酶缺乏症的高通量遗传和药物筛选
- 批准号:
7862206 - 财政年份:2009
- 资助金额:
$ 42.52万 - 项目类别:
Intracellular Serpin Regulation of Intestinal Cell Necrosis
细胞内丝氨酸蛋白酶抑制剂对肠细胞坏死的调节
- 批准号:
7729625 - 财政年份:2009
- 资助金额:
$ 42.52万 - 项目类别:
相似国自然基金
跨区域调水工程与区域经济增长:效应测度、机制探究与政策建议
- 批准号:72373114
- 批准年份:2023
- 资助金额:40 万元
- 项目类别:面上项目
农产品区域公用品牌地方政府干预机制与政策优化研究
- 批准号:72373068
- 批准年份:2023
- 资助金额:41 万元
- 项目类别:面上项目
新型城镇化与区域协调发展的机制与治理体系研究
- 批准号:72334006
- 批准年份:2023
- 资助金额:167 万元
- 项目类别:重点项目
我国西南地区节点城市在次区域跨国城市网络中的地位、功能和能级提升研究
- 批准号:72364037
- 批准年份:2023
- 资助金额:28 万元
- 项目类别:地区科学基金项目
多时序CT联合多区域数字病理早期预测胃癌新辅助化疗抵抗的研究
- 批准号:82360345
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
相似海外基金
Correction of Mucopolysaccharidosis type 1: Targeting safe harbor loci using genome editing
纠正 1 型粘多糖贮积症:使用基因组编辑瞄准安全港位点
- 批准号:
10213146 - 财政年份:2017
- 资助金额:
$ 42.52万 - 项目类别:
Correction of Mucopolysaccharidosis type 1: Targeting safe harbor loci using genome editing
纠正 1 型粘多糖贮积症:使用基因组编辑瞄准安全港位点
- 批准号:
9370576 - 财政年份:2017
- 资助金额:
$ 42.52万 - 项目类别:
Correction of Mucopolysaccharidosis type 1: Targeting safe harbor loci using genome editing
纠正 1 型粘多糖贮积症:使用基因组编辑瞄准安全港位点
- 批准号:
9524792 - 财政年份:2017
- 资助金额:
$ 42.52万 - 项目类别:
The Role of Language Experiences on Vocabulary Development: a Multidimensional, Developmental, and Individual Differences Analysis
语言经验对词汇发展的作用:多维、发展和个体差异分析
- 批准号:
8805295 - 财政年份:2015
- 资助金额:
$ 42.52万 - 项目类别: